Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
STRATEGIES FOR IMPROVING SURVIVAL IN MALIGNANT-MELANOMA - FOCUS ON VINDESINE
Autore:
RETSAS S;
Indirizzi:
CHARING CROSS HOSP,DEPT MED ONCOL,MELANOMA UNIT LONDON W6 8RF ENGLAND
Titolo Testata:
Journal of drug development and clinical practice
fascicolo: 3, volume: 7, anno: 1995,
pagine: 159 - 171
SICI:
1357-9215(1995)7:3<159:SFISIM>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Keywords:
MELANOMA; METASTATIC; CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY; VINDESINE; SURVIVAL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
NO
Recensione:
Indirizzi per estratti:
Citazione:
S. Retsas, "STRATEGIES FOR IMPROVING SURVIVAL IN MALIGNANT-MELANOMA - FOCUS ON VINDESINE", Journal of drug development and clinical practice, 7(3), 1995, pp. 159-171

Abstract

This paper summarises the systemic treatments used for metastatic melanoma in the Melanoma Unit at Charing Cross Hospital, UK, and offers an appraisal of adjuvant therapy with special emphasis on recent reports in the literature. Since 1977, patients presenting to this service with metastatic disease have been treated with protocols based primarily on vindesine as a single agent or in combinations with dacarbazine, platinum derivatives and fotemustine. Observed response rates ranged between 20% and 30% with the median duration of response not exceeding one year. Although the response rates ore not much higher with combination regimens than monotherapy, large tumour volumes involving multiple organ sites ore more likely to regress with polychemotherapy than single-agent treatment. Among 240 patients with widespread metastatic disease treated by these different vindesine-containing chemotherapy protocols and evaluated for survival, 36 (15%) survived longer than two years from onset of treatment Included among these long-term survivors were Patients with hepatic and cerebral metastases. Encouraging thoughthey may be, these results emphasise the need for adjuvant treatment in critical stages in the evolution of malignant melanoma. In the setting of clinical and histological metastases in the regional lymph nodes, adjuvant vindesine has been shown to result in a survival advantage. This and other studies are reviewed.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/07/20 alle ore 23:32:47